
The Kaival Brands Innovations Group has reported that its revenue for the third quarter of the 2022 fiscal year was $3.8 million, up from $3.2 million in the same period last year. The gross profit was $442,100, compared to a loss of $84,300 in the same period in 2021.
Photo credit: Crizzystudio.
Kaival attributed part of its revenue increase to a court ruling in August that suspended the Food and Drug Administration's (FDA) marketing denial order for its non-tobacco flavored Bidi Stick e-cigarette. The U.S. Eleventh Circuit Court of Appeals found that the FDA did not adequately consider Kaival Brands' marketing and sales access restriction plan, ordering the agency to further review Kaival's premarketing tobacco product application and allowing the company to continue selling its products.
In a statement, Eric Mosser, the President and Chief Operating Officer of Kaival Brands, expressed optimism following a recent decision by the 11th Circuit Court in favor of Bidi Vapor. Mosser believes that this decision will remove a significant obstacle to their B2B sales focus on adult consumers and enable them to expand their business, increase revenue, achieve net profitability, and enhance shareholder value in the future.
According to Mosser, the company is partnering with Philip Morris to expand international distribution into new global markets. In June, Kaival Brands Innovations Group's subsidiary, Kaival Brands International (KBI), signed a licensing agreement with Philip Morris Products (PMP) to develop and distribute electronic nicotine delivery system products outside the United States.
We anticipate recognizing revenue from this international licensing agreement in the fourth fiscal quarter," said Mosser.
In July, Kaival announced the launch of the Veeba steam products for PMP in Canada. They paid licensing fees to KBI according to the international licensing agreement.
Announcement:
This article is compiled from third-party information and is only intended for industry professionals to exchange and learn from.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only for the purpose of industry exchange and research.
Due to limitations in our translation abilities, the translated article may not accurately convey the original meaning. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.










